[go: up one dir, main page]

MX2017002328A - Analogos de dioxolano de uridina para el tratamiento del cancer. - Google Patents

Analogos de dioxolano de uridina para el tratamiento del cancer.

Info

Publication number
MX2017002328A
MX2017002328A MX2017002328A MX2017002328A MX2017002328A MX 2017002328 A MX2017002328 A MX 2017002328A MX 2017002328 A MX2017002328 A MX 2017002328A MX 2017002328 A MX2017002328 A MX 2017002328A MX 2017002328 A MX2017002328 A MX 2017002328A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
uridine
alkyl
dioxolane
Prior art date
Application number
MX2017002328A
Other languages
English (en)
Other versions
MX369649B (es
Inventor
BETHEL Richard
Eneroth Anders
Klasson Björn
Öberg Fredrik
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of MX2017002328A publication Critical patent/MX2017002328A/es
Publication of MX369649B publication Critical patent/MX369649B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención proporciona compuestos de la fórmula (I): en donde: R1 es OR11 o NR5R5', R2 es H o F; R5 es H, alquilo C1-C6, OH, C(=O)R6, O(C=O)R6 o O(C=O)OR6; R5' es H o alquilo C1-C6; R6 es alquilo C1-C6 o cicloalquilo C3-C7; R13 es H, fenilo, piridilo, bencilo, indolilo o naftilo, en donde el fenilo, piridilo, bencilo, indolilo y naftilo es opcionalmente sustituido con 1, 2 o 3 R22 y las otras variables son como se define en las reivindicaciones, que se utilizan en el tratamiento del cáncer y aspectos relacionados.
MX2017002328A 2014-08-25 2015-08-24 Analogos de dioxolano de uridina para el tratamiento del cancer. MX369649B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1450983 2014-08-25
SE1550858 2015-06-22
PCT/EP2015/069370 WO2016030335A1 (en) 2014-08-25 2015-08-24 Dioxolane analogues of uridine for the treatment of cancer

Publications (2)

Publication Number Publication Date
MX2017002328A true MX2017002328A (es) 2017-05-22
MX369649B MX369649B (es) 2019-11-15

Family

ID=54014804

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002328A MX369649B (es) 2014-08-25 2015-08-24 Analogos de dioxolano de uridina para el tratamiento del cancer.

Country Status (24)

Country Link
US (7) US10144750B2 (es)
EP (2) EP3186244B1 (es)
JP (2) JP6663424B2 (es)
KR (2) KR102398714B1 (es)
CN (4) CN107074826B (es)
AU (2) AU2015308988C1 (es)
BR (1) BR112017003898B1 (es)
CA (2) CA3128645C (es)
CY (1) CY1122945T1 (es)
DK (2) DK3186244T3 (es)
EA (2) EA031106B1 (es)
ES (2) ES2796089T3 (es)
HR (1) HRP20201023T1 (es)
HU (2) HUE059640T2 (es)
IL (2) IL250344B (es)
MX (1) MX369649B (es)
MY (2) MY188089A (es)
NZ (2) NZ729118A (es)
PH (2) PH12017500184B1 (es)
PL (2) PL3186244T3 (es)
PT (2) PT3186244T (es)
SG (3) SG10202001117YA (es)
WO (1) WO2016030335A1 (es)
ZA (1) ZA201802864B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2796089T3 (es) * 2014-08-25 2020-11-25 Medivir Ab Análogos de dioxano de uridina para el tratamiento de cáncer
CN106543220A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
JP6889180B2 (ja) 2015-12-11 2021-06-18 ニューカナ パブリック リミテッド カンパニー ホスフェート誘導体及びゲムシタビンプロドラッグｎｕｃ−１０３１のジアステレオ選択性合成
US10456413B2 (en) * 2016-03-02 2019-10-29 Medivir Aktiebolag Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
CN106432328B (zh) * 2016-09-14 2019-03-22 江苏福瑞生物医药有限公司 一种索非布韦中间体的制备方法
AU2017361855A1 (en) * 2016-11-18 2019-05-30 Neurovive Pharmaceutical Ab Liver prodrugs of mitochondrial proton ionophores
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
WO2019245444A1 (en) 2018-06-21 2019-12-26 Medivir Ab Base-modified cytidine nucleotides for leukemia therapy
HUE065972T2 (hu) * 2019-02-18 2024-06-28 Medivir Ab Gyógyszerkombináció a májrák kezelésére szolgáló eljárásban történõ alkalmazásra
CN110964057B (zh) * 2019-12-25 2022-05-06 东南大学 一种利用微流体反应装置制备索非布韦中间体的方法
CN113402546A (zh) * 2020-03-17 2021-09-17 浙江四维医药科技有限公司 一种瑞德西韦磷酸中间体尾链动态动力学拆分方法
TW202200140A (zh) * 2020-04-15 2022-01-01 瑞典商米迪維艾克提伯拉公司 用於肝癌之miv-818/樂伐替尼(lenvatinib)組合療法
CN113754692B (zh) * 2020-06-03 2022-06-10 上海交通大学 瑞德西韦中间体(s,s)-氨基磷酸酯的不对称催化合成方法
CN114685558A (zh) * 2020-12-28 2022-07-01 尚科生物医药（上海）有限公司 一种瑞德西韦中间体的制备方法
CN114249764A (zh) * 2021-11-10 2022-03-29 宁波大学 一种磷酰胺酯类前药的中间体及其制备方法与应用
WO2025155547A1 (en) * 2024-01-17 2025-07-24 University Of Georgia Research Foundation, Inc. An efficient synthesis of beta-l-5-[(e)-2-bromovinyl)-1-((2s,4s)-2-(hydroxymethyl)-1,3-(dioxolane-4-yl) uracil)] (l-bhdu) via chiral pure l-dioxolane

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6022876A (en) 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
HUP0301363A2 (hu) * 2000-10-13 2005-12-28 Shire Biochem Inc. Javított intercelluláris bejuttathatóságú dioxolán analógok
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2007106450A2 (en) * 2006-03-10 2007-09-20 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy
KR20090057050A (ko) * 2006-09-01 2009-06-03 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 암치료를 위한 트록사시타빈 전구약물
PL216525B1 (pl) * 2006-10-17 2014-04-30 Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk 5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
KR20160099090A (ko) * 2013-11-27 2016-08-19 아이데닉스 파마슈티칼스 엘엘씨 간암의 치료를 위한 뉴클레오티드
ES2796089T3 (es) * 2014-08-25 2020-11-25 Medivir Ab Análogos de dioxano de uridina para el tratamiento de cáncer

Also Published As

Publication number Publication date
HUE059640T2 (hu) 2022-12-28
PH12017500184A1 (en) 2017-06-28
KR20200035482A (ko) 2020-04-03
PT3186244T (pt) 2020-05-29
PL3186244T3 (pl) 2020-11-16
JP6663424B2 (ja) 2020-03-11
PL3572410T3 (pl) 2022-10-03
IL250344B (en) 2020-01-30
CN111269264A (zh) 2020-06-12
US10336780B2 (en) 2019-07-02
EP3186244B1 (en) 2020-04-22
CA2956251C (en) 2022-10-25
IL266766B (en) 2020-05-31
CN110804072A (zh) 2020-02-18
KR102398714B1 (ko) 2022-05-17
EP3572410A1 (en) 2019-11-27
HRP20201023T1 (hr) 2020-10-16
ES2927212T3 (es) 2022-11-03
HUE050705T2 (hu) 2020-12-28
EP3186244A1 (en) 2017-07-05
DK3572410T3 (da) 2022-08-29
JP6905609B2 (ja) 2021-07-21
NZ762628A (en) 2023-04-28
US10822360B2 (en) 2020-11-03
US20170267705A1 (en) 2017-09-21
MX369649B (es) 2019-11-15
IL266766A (en) 2019-07-31
JP2020090535A (ja) 2020-06-11
BR112017003898B1 (pt) 2022-10-18
AU2015308988C1 (en) 2018-09-06
US20210054008A1 (en) 2021-02-25
CN107074826B (zh) 2020-05-22
EA201890648A2 (ru) 2018-08-31
CN110790789B (zh) 2023-05-12
US10654877B2 (en) 2020-05-19
SG10201911558UA (en) 2020-01-30
US10144750B2 (en) 2018-12-04
MY198325A (en) 2023-08-24
KR102396905B1 (ko) 2022-05-13
PH12019501919A1 (en) 2020-09-14
EP3572410B1 (en) 2022-07-20
AU2015308988B2 (en) 2018-04-26
CA2956251A1 (en) 2016-03-03
US20230382931A1 (en) 2023-11-30
US20190389890A1 (en) 2019-12-26
ZA201802864B (en) 2019-07-31
MY188089A (en) 2021-11-17
NZ729118A (en) 2022-02-25
KR20170046736A (ko) 2017-05-02
SG11201701172SA (en) 2017-03-30
EA031106B1 (ru) 2018-11-30
AU2018201980B2 (en) 2019-05-16
EA033300B1 (ru) 2019-09-30
IL250344A0 (en) 2017-03-30
CA3128645C (en) 2023-06-27
EA201890648A3 (ru) 2019-02-28
US11447511B2 (en) 2022-09-20
PT3572410T (pt) 2022-09-15
CA3128645A1 (en) 2016-03-03
AU2015308988A1 (en) 2017-02-23
AU2018201980A1 (en) 2018-04-12
CY1122945T1 (el) 2021-10-29
ES2796089T3 (es) 2020-11-25
EA201790328A1 (ru) 2017-08-31
CN107074826A (zh) 2017-08-18
PH12017500184B1 (en) 2017-06-28
CN110790789A (zh) 2020-02-14
CN110804072B (zh) 2023-05-12
US20190100541A1 (en) 2019-04-04
SG10202001117YA (en) 2020-04-29
JP2017526677A (ja) 2017-09-14
DK3186244T3 (da) 2020-07-13
BR112017003898A2 (pt) 2017-12-05
US20200239502A1 (en) 2020-07-30
WO2016030335A1 (en) 2016-03-03
US20230117570A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
MX2017002328A (es) Analogos de dioxolano de uridina para el tratamiento del cancer.
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
JOP20190194B1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
EA201892147A1 (ru) Бициклические соединения
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
ECSP18012103A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
EA201691857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
CU20170015A7 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201691913A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
JO3466B1 (ar) مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
PH12016501941A1 (en) Use of heterocyclic compounds for controlling nematodes
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
SV2017005381A (es) Compuestos de imidazopiridazina
EA201692525A1 (ru) Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов
ECSP17010238A (es) Compuestos novedosos de pirimidina sustituidos
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
EA201691999A1 (ru) Новые сульфониламинобензамидные соединения
MX378601B (es) Derivados de dipicolilamina y sus usos farmaceuticos.
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
MX2019008375A (es) Tiobenzoimidazol como fungicidas.
EA201792502A1 (ru) Кабазитаксел и его применение для лечения рака
ECSP17046657A (es) Síntesis total de trioxacarcina dc-45-a2 y preparación de análogos de trioxacarcina

Legal Events

Date Code Title Description
FG Grant or registration